Immunovant, Inc.
IMVT
$25.75
$0.110.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -11.85% | -32.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.21% | 3.57% | |||
| Operating Income | 13.21% | -3.57% | |||
| Income Before Tax | 13.36% | -5.19% | |||
| Income Tax Expenses | 161.28% | -34.94% | |||
| Earnings from Continuing Operations | 12.54% | -4.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.54% | -4.88% | |||
| EBIT | 13.21% | -3.57% | |||
| EBITDA | 13.21% | -3.57% | |||
| EPS Basic | 16.33% | -3.20% | |||
| Normalized Basic EPS | 17.12% | -3.52% | |||
| EPS Diluted | 16.33% | -3.20% | |||
| Normalized Diluted EPS | 17.12% | -3.52% | |||
| Average Basic Shares Outstanding | 4.53% | 1.62% | |||
| Average Diluted Shares Outstanding | 4.53% | 1.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||